P/E at 29.61 vs Industry's 37.21: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amid Sector Premiums

The current P/E ratio of Dr Reddys Laboratories Ltd at 29.61 stands well below the industry average of 37.21, indicating the stock is trading at a 20% discount relative to its sector peers. This valuation gap suggests the market is pricing in either near-term challenges or a more cautious outlook compared to the broader Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, but Dr Reddys Laboratories Ltd appears to be viewed more conservatively. Is this valuation discount justified by fundamentals or a potential opportunity? The data suggests a nuanced picture.

Performance Across Timeframes: Divergent Momentum

Examining returns reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 12.56%, underperforming the Sensex’s 8.03% loss. However, the shorter three-month period shows a more pronounced underperformance with a 10.34% drop, while the Sensex gained 1.22%. This divergence indicates that recent quarters have been particularly challenging for the stock, possibly reflecting sector-specific headwinds or company-specific issues. Conversely, the one-month and one-week performances (-1.47% and -1.27% respectively) are less severe than the three-month slide, hinting at some stabilisation. Is this a temporary pause in the downtrend or a sign of deeper weakness?

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd remains bearish. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained downward pressure. This configuration typically signals a continuation of the downtrend or at best a prolonged consolidation phase. The absence of any short-term moving average support suggests that recent price action has failed to generate meaningful recovery momentum. The 5% weekly decline partially reverses a steeper monthly drop — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The technicals currently lean towards caution.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed earnings results so far, with 34 stocks having declared results: 14 positive, 15 flat, and 5 negative. This distribution suggests a broadly neutral to slightly positive sector environment, though not without pockets of weakness. Dr Reddys Laboratories Ltd’s underperformance relative to the sector’s mixed results may reflect company-specific challenges or competitive pressures. The sector’s average P/E of 37.21 underscores investor optimism in select names, contrasting with Dr Reddys Laboratories Ltd’s more cautious valuation.

Rating Context: Previously Hold, Now Reassessed

According to MarketsMOJO, Dr Reddys Laboratories Ltd was previously rated Hold before the rating was updated on 13 Jul 2026. While the current rating is undisclosed, the reassessment coincides with the stock’s valuation discount and recent underperformance. The Mojo Score of 30.0 and mid-cap market capitalisation of ₹95,178.55 crores position the company as a significant player within the Pharmaceuticals & Biotechnology sector, yet the data suggests caution. What is the current rating and how does it reflect the evolving fundamentals?

Comparative Performance: Underwhelming Long-Term Returns

Longer-term returns for Dr Reddys Laboratories Ltd also lag the Sensex. Over three years, the stock has gained 2.13% compared to the Sensex’s 12.45%. Over five years, the stock’s 16.01% return trails the Sensex’s 28.44%, and over ten years, the stock’s 78.57% gain is significantly below the Sensex’s 160.05%. This persistent underperformance highlights challenges in generating alpha over extended periods. The stock’s current valuation discount may partly reflect this historical trend, though it also raises questions about whether the market is pricing in structural issues or cyclical pressures. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The current rating provides the answer.

Intraday and Short-Term Movements

On 10 Sep 2026, Dr Reddys Laboratories Ltd declined marginally by 0.25%, moving in line with the Pharmaceuticals & Biotechnology sector’s flat performance. The stock’s inability to break above any of its key moving averages suggests that short-term momentum remains weak. This lack of positive price action reinforces the cautious stance reflected in the valuation and rating reassessment. Is this consolidation phase a precursor to a trend reversal or a continuation of the downtrend?

Summary: What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd paints a picture of a stock trading at a meaningful discount to its sector’s valuation, yet burdened by underperformance across multiple timeframes and a bearish technical setup. The reassessment from a previous Hold rating reflects these challenges. While the sector shows a mixed earnings environment, Dr Reddys Laboratories Ltd’s relative weakness and persistent lag behind the Sensex over the long term raise questions about its near-term prospects. What is the current rating and how should investors interpret this evolving data?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →